Mechanism-Matched Pharmacology of Resistance in EGFR-Mutant NSCLC: Genomic Bypass, Lineage Plasticity, Antibody-Drug Conjugates, and Candidate Biophysical Targets
- 1Department of Physiology, Dongguk University College of Medicine, 123 Dongdae-ro, Gyeongju-si 38066, Gyeongsangbuk-do, Republic of Korea
Abstract
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) often responds to EGFR tyrosine kinase inhibitors but develops heterogeneous resistance. This structured narrative review integrates clinical and experimental evidence on resistance after osimertinib and intensified EGFR-directed therapy. It distinguishes on-target EGFR alterations, MET and ERBB-family bypass, downstream signaling, oncogenic fusions, histologic transformation, epithelial–mesenchymal plasticity, and drug-tolerant persistence, linking each mechanism to an appropriate assay and treatment context. We evaluate next-generation EGFR inhibitors, EGFR-MET combinations, bispecific antibodies, platinum-pemetrexed intensification, and antibody-drug conjugates directed at HER3, TROP2, or HER2. Clinical validation is assessed separately from mechanistic causality, with attention to allelic phase, central nervous system exposure, target engagement, unbound drug concentration, predictive biomarkers, and safety. Ion channels and transporters, including ANO1/TMEM16A, LRRC8/VRAC, KCa3.1, hERG, STIM-ORAI, TRP, and pH regulators, remain exploratory candidate targets. Available evidence for their role in acquired osimertinib resistance is largely indirect; expression or general tumor biology does not establish disease-specific dependency. A mechanism-matched development pathway using paired tissue and plasma sampling, relevant resistant models, causal perturbation, and pharmacodynamic validation is proposed. Clinical decisions should follow validated mechanisms rather than extrapolated biophysical hypotheses.
Related
- From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates
- Integrated network pharmacology, in vivo experiment, computational biology, and metabolomics to explore the mechanism of astragaloside IV against spinal cord injury
- Low-dose doxorubicin drives caveolin-1 depended re-epithelialization of breast cancer cells as a mechanism of cancer plasticity
- Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism
- Mechanism of Pingchuanning in Attenuating Asthma Based on UHPLC-Q-Orbitrap HRMS and Network Pharmacology Analysis.
BibTeX
@article{seo2026mechanismmatched,
title = {{Mechanism-Matched Pharmacology of Resistance in EGFR-Mutant NSCLC: Genomic Bypass, Lineage Plasticity, Antibody-Drug Conjugates, and Candidate Biophysical Targets}},
author = {Yohan Seo},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219569},
url = {https://www.mdpi.com/1422-0067/27/21/9569},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Mechanism-Matched Pharmacology of Resistance in EGFR-Mutant NSCLC: Genomic Bypass, Lineage Plasticity, Antibody-Drug Conjugates, and Candidate Biophysical Targets
AU - Yohan Seo
PY - 2026
DA - 2026/10/26
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219569
UR - https://www.mdpi.com/1422-0067/27/21/9569
AB - Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) often responds to EGFR tyrosine kinase inhibitors but develops heterogeneous resistance. This structured narrative review integrates clinical and experimental evidence on resistance after osimertinib and intensified EGFR-directed therapy. It distinguishes on-target EGFR alterations, MET and ERBB-family bypass, downstream signaling, oncogenic fusions, histologic transformation, epithelial–mesenchymal plasticity, and drug-tolerant persistence, linking each mechanism to an appropriate assay and treatment context. We evaluate next-generation EGFR inhibitors, EGFR-MET combinations, bispecific antibodies, platinum-pemetrexed intensification, and antibody-drug conjugates directed at HER3, TROP2, or HER2. Clinical validation is assessed separately from mechanistic causality, with attention to allelic phase, central nervous system exposure, target engagement, unbound drug concentration, predictive biomarkers, and safety. Ion channels and transporters, including ANO1/TMEM16A, LRRC8/VRAC, KCa3.1, hERG, STIM-ORAI, TRP, and pH regulators, remain exploratory candidate targets. Available evidence for their role in acquired osimertinib resistance is largely indirect; expression or general tumor biology does not establish disease-specific dependency. A mechanism-matched development pathway using paired tissue and plasma sampling, relevant resistant models, causal perturbation, and pharmacodynamic validation is proposed. Clinical decisions should follow validated mechanisms rather than extrapolated biophysical hypotheses.
SN - 1422-0067
ER -